A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix

Stehman, Frederick B.; Bundy, Brian N.; Keys, Henry; Currie, John L.; Mortel, Rodrique; Creasman, William T.

doi:10.1016/0002-9378(88)90499-1

Cited by 54 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 The Gynecologic Oncology Group has performed several prospective, randomized studies of the effect of concurrent chemotherapy and radiotherapy in women with locally advanced cervical cancer. Radio-therapy combined with treatment with hydroxyurea has been compared in separate trials with radiotherapy alone, with radiotherapy and concomitant therapy with misonidazole, and with radiotherapy and concomitant treatment with cisplatin and fluorouracil [11][12][13] (and Whitney CW: unpublished data). As compared with radiotherapy alone, treatment with hydroxyurea and radiotherapy significantly increased the rate of complete response, progression-free survival, and overall survival.…”

mentioning

confidence: 99%

“…11 As compared with treatment with misonidazole and radiotherapy, treatment with hydroxyurea and radiotherapy increased progressionfree survival and was less toxic. 12,13 However, treatment with cisplatin, fluorouracil, and radiotherapy resulted in greater improvement in progression-free survival and overall survival than did treatment with hydroxyurea and radiotherapy (Whitney CW: unpublished data).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

et al. 1999

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

et al. 1999

Self Cite

View full text Add to dashboard Cite

show abstract

“…Local control and distant metastases have been 08/, and as noted in the current series, continue to be a major source of failure in advanced stage cervical cancer treated by radiation therapy. To date, chemotherapy in advanced cervical cancer has been utilized mainly as a radiation potentiator (19' 2°) without significant impact on distant disease (21). The GaG currently is investigating potential treatment strategies to enhance local control, potentially increasing distal control in the systemic chemotherapy therapy arms, in patients with negative para-aortic lymph node metastases as determined by staging laparotomy.…”

Section: Discussionmentioning

confidence: 99%

The influence of staging laparotomy for cervical cancer on patterns of recurrence and survival

Potter

Spencer²,

Soong

et al. 1993

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

A matched paired study of surgically staged and non-surgically staged patients with stage II and III cervical carcinoma from October 1974 through August 1987 was retrospectively performed. Eight of 55 (13.8%) had para-aortic lymph node involvement. After tailored extended field radiation 2/8 (25%) remain alive without evidence of disease. Patient survival although slightly in favor of the unstaged group was similar. Patterns of recurrence were similar amongst treatment groups. Para-aortic nodal recurrence, despite tailored radiation therapy, was identical (5.4%) in the staged and unstaged groups. Only one patient (not surgically staged) had an isolated para-aortic recurrence. With the morbidity of an operative procedure and similar survival rates and para-aortic nodal recurrence rates, the value of staging laparotomy in improved patient survival is questioned. Pelvic failure and other distant metastases continue to be the major sites of recurrences.

show abstract

“…Although there were concerns about methods and execution in this early trial (91), concurrent HU was accepted by GOG as a standard for comparison with new approaches. GOG 56 compared HU vs. the hypoxic cell sensitizer, misonidazole, concurrent with pelvic RT; the outcome favored HU (p= 0.066) but not significantly (92). …”

Section: Cervical Carcinomamentioning

confidence: 99%

Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience

Omura

2008

Seminars in Oncology

View full text Add to dashboard Cite

Since 1970, the Gynecologic Oncology Group (GOG) has been a leader in clinical research in gynecologic oncology. Currently comprising fifty-nine institutions and their affiliates in the United States, Canada and elsewhere, GOG has defined, principally through phase III randomized clinical trials, the standard of care for several stages and types of female pelvic cancer. This review will briefly summarize, in the context of research done concurrently by other groups and institutions, important GOG trials that have moved the field forward, especially in ovarian, endometrial, and cervical cancer. The role of cisplatin, carboplatin and paclitaxel as well as other drugs and combinations in gynecologic cancer has been extensively studied by GOG, as has chemoradiation in cervical cancer. Surgical staging of cervical and endometrial cancers has provided new insights and guidance for management. The benefits and limitations of radiation therapy in these diseases have been carefully examined. Thus, the stage has been set for further progress in this field.

show abstract

A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix

Cited by 54 publications

References 9 publications

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer

The influence of staging laparotomy for cervical cancer on patterns of recurrence and survival

Progress in Gynecologic Cancer Research: The Gynecologic Oncology Group Experience

Contact Info

Product

Resources

About